A NEW patented non-steroidal treatment for eczema called Curezma has launched in Australia, offering relief, and addressing the root causes of this debilitating skin condition.
Founders Aditi Brahmachari and Jai Uniyal developed Curezma after embarking on a quest to alleviate their daughter's eczema struggles. At the time, a steroid-free solution was not available.
The hypoallergenic formulation range was created after more than three years of rigorous research, testing and development by scientists at Arete Labs.
Brahmachari, a cosmeceutical scientist, led the R&D team and they worked tirelessly on developing this breakthrough patented treatment.
A TGA-listed and clinically proven product, Curezma contains a blend of naturally derived ingredients designed to reduce inflammation, itch and trans-epidermal water loss.
It enhances skin elasticity and repairs skin barrier function without the use of steroids, parabens, or sulfates.
Its effectiveness was validated in one of Australia's largest skincare clinical trials, involving over 170 participants at the globally recognised Princeton Consumer Research in the UK.
According to the results, 100% of users saw reduction in inflammation, 97% reported instant relief from itching and 82% experienced overall improved skin elasticity.
The Curezma eczema-care range includes oil, ointment, serum, and cleanser suitable for babies, kids and adults.
Products are priced between $14.98 and $39.98.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 May 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 May 24
